Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Neurology - 26 Oct 2010

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre J-Y

Abstract excerpt

OBJECTIVES: Recent studies have shown that IDH1 and IDH2 mutations occur frequently in gliomas, including low-grade gliomas. However, their impact on the prognosis and chemosensitivity of low-grade gliomas remains unclear. METHODS: Search for IDH1 and IDH2 mutations, loss of heterozygosity on chromosomes 1p and 19q, MGMT promoter methylation, and p53 expression was performed in a series of 271 low-grade gliomas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Statistics as Topic

Share to Temozolomide

Source

Identifiers

PMID: 20975057
DOI: 10.1212/WNL.0b013e3181f96282

Genes

IDH1
IDH2
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.PMID 20975057Read ↗

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.Semantic proximity Read ↗

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Semantic proximity Read ↗

The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?Semantic proximity Read ↗

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.Semantic proximity Read ↗

IDH mutations: genotype-phenotype correlation and prognostic impact.Semantic proximity Read ↗

Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.Semantic proximity Read ↗

Thirty years of progress in the management of low-grade gliomas.Semantic proximity Read ↗

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.Semantic proximity Read ↗

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.Semantic proximity Read ↗

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.Semantic proximity Read ↗

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.Semantic proximity Read ↗

A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.